กำลังโหลด
NASDAQHealthcareBiotechnology
ข้อมูลล่าสุด
US$4.95
−US$0.04 · -0.80%
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
ราคาปิดก่อนหน้า
US$4.95
−US$0.04 · -0.80%
หลังปิดตลาด
US$5.05
+US$0.10 · +2.02%
9 ต.ค. 19:51 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
ช่วงราคารายวัน
ปัจจุบัน US$4.95
ช่วง 52 สัปดาห์
ปัจจุบัน US$4.95
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
84
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
59
ผสม
ความเสี่ยง
58
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
60
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
ช่วงราคารายวัน
ปัจจุบัน US$4.95
ช่วง 52 สัปดาห์
ปัจจุบัน US$4.95
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$12.00
โอกาสปรับขึ้น 142.42%ไม่มีประวัติราคา
สูง: US$12.00เฉลี่ย: US$12.00ต่ำ: US$12.00กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI2.74M0.00%2.3T USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF1.05M0.00%95.4B USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS459.39K0.00%33.87B USD0.31%US$78.35+0.32%
iShares Micro-Cap ETFIWC311.56K0.02%1.32B USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC192.23K0.00%7.56B USD0.43%US$57.813+0.20%
Avantis U.S. Small Cap Equity ETFAVSC55.98K—3.06B USD0.25%US$69.98+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV41.41K0.00%6.18B USD0.26%US$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC27.3K0.00%88.6B USD0.21%US$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
